
Twist Bioscience Corporation
-3.37 %
38.89 %
Yet to be announced
Company Overview
Twist Bioscience Corporation is a biotechnology company that manufactures and sells synthetic DNA-based products. The company specializes in DNA synthesis platforms, offering a wide range of synthetic biology tools including synthetic genes, DNA libraries, and oligo pools. Their technology enables customers in various fields including healthcare, agriculture, industrial chemicals, and academic research to accelerate their research and development efforts.
The company's primary focus is on developing synthetic DNA and optimizing the DNA synthesis process to make it more efficient and cost-effective. Their proprietary technology platform allows for the parallel synthesis of DNA on silicon platforms containing hundreds of thousands of individual wells.
Revenue Sources
PassBased on SEC filings and company reports, Twist Bioscience's revenue primarily comes from the sale of synthetic DNA products and related services. Their business model focuses on providing synthetic biology tools and solutions, which are halal activities as they involve the creation and sale of actual products and services that benefit society through medical research and technological advancement.
The company does not derive revenue from prohibited activities such as alcohol, tobacco, gambling, or interest-based financial services.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Dec. 31, 2024 | $88.71m | $123.38m | - | $24,000 | 0.00% | 0.02% |
Sept. 30, 2024 | $84.71m | $120.78m | - | $29,000 | 0.00% | 0.02% |
June 30, 2024 | $81.46m | $170.39m | - | - | 0.00% | 0.00% |
March 31, 2024 | $75.3m | $124.19m | - | - | 0.00% | 0.00% |
Analysis of the company's financial statements over the past four quarters shows minimal interest expenses. The company reported interest expense of $29,000 in one quarter and zero in the other three quarters. The interest expense ratio to total expenses is well below the 5% threshold for all quarters. Additionally, the company reported no interest income across all four quarters.
Operational Ethics
PassBased on available information from SEC filings and company disclosures, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's primary operations are in the United States, and there are no documented current material relationships with the state of Israel or the Chinese Communist Party.
Login to join the discussion